Macrocyclic PD-1 Inhibitors for Immune Evasion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective agents that can inhibit the interaction between PD-1 and PD-L1, which is crucial for reversing immune suppression and enhancing anti-tumor and anti-infectious disease responses.
Innovation Solution
Development of macrocyclic compounds that specifically bind to the PD-1 protein, thereby inhibiting its interaction with PD-L1, and are administered as pharmaceutical compositions to enhance immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment is provided, but they lack effective agents to inhibit PD-1/PD-L1 interaction
Solution Approach 1:
The patent employs parameter changes by developing macrocyclic compounds with specific molecular structures (Formula I) that bind to PD-1 with optimized affinity and specificity. The chemical parameters of the compounds are systematically varied to enhance their ability to inhibit PD-1/PD-L1 interaction, thereby improving therapeutic efficacy where previous agents were ineffective.
2Reliability
If macrocyclic compounds are developed to bind PD-1, then immune response enhancement is achieved, but drug development complexity increases
Solution Approach 1:
The patent applies segmentation by defining the macrocyclic compound structure in Formula I with distinct variable regions (R1-R17 substituents) that can be independently optimized. This modular approach allows systematic development of compound libraries with different immunomodulatory properties, managing development complexity through structured molecular design rather than random screening.
Solution Approach 2:
The patent achieves universality by designing macrocyclic compounds that can simultaneously bind PD-1 and modulate multiple immune responses. The compounds are intended to treat various diseases including cancer and infectious diseases, providing a multi-functional therapeutic agent that addresses diverse pathological conditions through a single molecular platform.
3Reliability
If PD-1/PD-L1 interaction is blocked, then immune suppression is reversed, but off-target effects may occur
Solution Approach 1:
The patent applies local quality by designing macrocyclic compounds with specific structural features (substituents at defined positions in Formula I) that target the PD-1 binding interface with high precision. The localized molecular interactions at the PD-1 binding site enhance specificity, minimizing off-target effects while maintaining effective blockade of the PD-1/PD-L1 interaction pathway.
Data Source
AI summary
In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-I and are capable of inhibiting the interaction of PD-I with PD-LI. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.